Exercise News and Research

Latest Exercise News and Research

American Specialty Health named to fastest-growing company list on 2010 Inc. 5000

Health and wellness company American Specialty Health Incorporated (ASH) was recently named to Inc. magazine's fourth annual list of the 5,000 fastest growing privately-held companies in the United States for a second consecutive year. The list is a comprehensive look at one of the most important segments of the economy—America's independent-minded entrepreneurs—and serves as a unique illustration of the profound changes taking place in the U.S. economy.

11 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

Abbott to withdraw sibutramine from Canadian market

Abbott will voluntarily withdraw sibutramine from the Canadian market after discussion with Health Canada. Sibutramine is marketed by Abbott in Canada as Meridia.

11 Oct 2010

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing System (DPS) as a Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis (ALS) patients with a stimulatable diaphragm who are experiencing chronic hypoventilation and has now submitted for Humanitarian Device Exemption (HDE) approval.

11 Oct 2010

Cytomedix secures $13 million in registered direct offering under equity purchase agreements

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today that the Company has secured approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements.

11 Oct 2010

Orthopaedic surgeons offer safety tips for marathon runners

On the brink of Chicago's popular marathon, 45,000 marathon runners from all 50 states and more than 100 countries will turn corners and pick up their pace for the big race in October.

8 Oct 2010

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant (p<0.05) reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes

8 Oct 2010

Orchid Cellmark conducts DNA analysis for five U.K. police forces

Orchid Cellmark Inc., a leading international provider of identity DNA testing services, today announced that it has now started work for five U.K. police forces in the East Midlands region, under contracts awarded following the latest National Forensic Procurement regional tender.

8 Oct 2010

Cyclacel announces completion of private placement sale

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that it consummated its previously announced private placement to sell approximately $15.2 million of its units to several institutional investors, including the Special Situations Funds, for net proceeds of approximately $14.1 million after the deduction of offering expenses.

7 Oct 2010

Sucampo submits marketing application for Amitiza drug

Sucampo Pharmaceuticals, Inc. and Abbott today announced that Sucampo Pharma Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc., has submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market Amitiza (lubiprostone) 24 mcg for the treatment of chronic idiopathic constipation (CIC).

7 Oct 2010

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades.

7 Oct 2010

Waist size can predict diabetes risk

A higher rate of diabetes seen among adult Americans when compared to peers in England is explained primarily by a larger waist size rather than conventional risk factors such as obesity, according to a new study by researchers from the RAND Corporation, University College London and the Institute for Fiscal Studies in London.

7 Oct 2010

Faith-based interventions effective in changing behavior among older African-American women: Study

In a randomized controlled study based in Los Angeles, California, encouraging African-American women aged 60 or over to exercise, in conjunction with scripture reading and group prayer, led to a 78% increase in steps per week, equivalent to about three extra miles. This increase was four times greater than in the control group who were also encouraged to exercise but with no faith based interventions.

7 Oct 2010

Chelsea Therapeutics announces underwriters exercise 1.07 million additional shares to cover over-allotments

Chelsea Therapeutics International, Ltd. has completed its previously announced public offering of common stock and announced that the underwriters exercised their option to purchase approximately 1.07 million additional shares to cover over-allotments.

7 Oct 2010

SOKO signs revenue-sharing agreement with Bin Xian for education offering

SOKO Fitness & Spa Group, Inc., an operator of fitness centers, beauty salons and spas in Northeast China as well as suburban Beijing, today announced that it has signed a cooperation and revenue-sharing agreement with Bin Xian Vocational Technology and Education Center ("Bin Xian"), which is located in suburban Harbin, China.

6 Oct 2010

American Specialty Health and Healthyroads move to San Diego's Sorrento Mesa business district

It's moving month for health and wellness company American Specialty Health Incorporated (ASH) and its subsidiaries, including wellness company Healthyroads. ASH will be vacating its 156,000 square feet of existing office space in downtown San Diego and transitioning to a 20 percent larger campus environment, comprised of an 81,000 square-foot building to house Healthyroads and a 107,000 square foot building for ASH's other programs. The new buildings, which ASH will occupy for the next 10 years, are located in San Diego's Sorrento Mesa business district.

6 Oct 2010

Research suggests carotenoids can support women's health

Only about a third of American women are meeting their fruit and vegetable intake recommendations, which means they are likely missing out on potentially important breast and ovarian health benefits. Along with vitamins, minerals and fiber, fruits and vegetables contain a type of phytonutrient called carotenoids, which research suggests help support women's health including breast and ovarian health.

6 Oct 2010

Healthcare organizations urge Congress to raise awareness on sudden cardiac arrest

In a powerful demonstration of collective standing in the health care community, more than 40 organizations gathered on Capitol Hill to issue a call to action in reducing sudden cardiac arrest (SCA) deaths.

6 Oct 2010

Researchers to conduct trial to improve drug abstinence, relapse rates

A $15.7 million award from the National Institute on Drug Abuse (NIDA) is allowing researchers to see whether consistent exercise will help people abstain from stimulant abuse.

6 Oct 2010

Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD

Aeterna Zentaris Inc., today announced that an interim review of a Phase 3 trial of AEZS-130 (macimorelin, SolorelTM), demonstrates the compound may provide a simple, well-tolerated and safe oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). The data was presented earlier today by Beverly M.K. Biller, M.D. of the Harvard Medical School/Massachusetts General Hospital in Boston, at the 5th International Congress of the Growth Hormone Research Society (GRS) and the Insulin-like Growth Factors (IGF) Society in New York City.

6 Oct 2010

Exercise News and Research

Latest Exercise News and Research

American Specialty Health named to fastest-growing company list on 2010 Inc. 5000

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Abbott to withdraw sibutramine from Canadian market

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Cytomedix secures $13 million in registered direct offering under equity purchase agreements

Orthopaedic surgeons offer safety tips for marathon runners

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

Orchid Cellmark conducts DNA analysis for five U.K. police forces

Cyclacel announces completion of private placement sale

Sucampo submits marketing application for Amitiza drug

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Waist size can predict diabetes risk

Faith-based interventions effective in changing behavior among older African-American women: Study

Chelsea Therapeutics announces underwriters exercise 1.07 million additional shares to cover over-allotments

SOKO signs revenue-sharing agreement with Bin Xian for education offering

American Specialty Health and Healthyroads move to San Diego's Sorrento Mesa business district

Research suggests carotenoids can support women's health

Healthcare organizations urge Congress to raise awareness on sudden cardiac arrest

Researchers to conduct trial to improve drug abstinence, relapse rates

Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD

Innovation in neuroscience drug discovery - eBook eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Exercise News and Research

Latest Exercise News and Research

Innovation in neuroscience drug discovery - eBook eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in